SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Enzo Biochemical Inc. A biotechnology Co. with earnings.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Kevin Clarke who wrote (165)9/9/2000 8:41:01 PM
From: greedsgd_2000  Read Replies (1) of 184
 
ENZ does have an HIV gene therapy program at the pre-phase 2 stage, however, I have not they have "the cure"

With ENZ Basically your buying a low risk, absurdly undervalued biotech, given the resources and track record they have. Management here is known to understate prospects going forward, and appear to be very anti-hype. They believe the stock price will flow from the science.

They in fact actually have earnings, rare among biotechs.
Basically a low risk biotech company, which has been around many yrs - and will continue as a strong presence.

In ref to AIDs, I think HEPH might be watched closely. If something big happens, that might be one of the key companies - at least in the area of preventing HIV carriers from going into full blown Aids. Financial risk there is much higher than ENZ, of course.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News